News articles about Marinus Pharmaceuticals (NASDAQ:MRNS) have trended somewhat positive on Saturday, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Marinus Pharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.1998407406354 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
A number of equities research analysts have recently issued reports on MRNS shares. ValuEngine lowered Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Laidlaw started coverage on Marinus Pharmaceuticals in a research report on Thursday, December 14th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, BidaskClub lowered Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th.
Shares of Marinus Pharmaceuticals (MRNS) traded down $0.23 during trading on Friday, reaching $7.34. The company had a trading volume of 615,545 shares, compared to its average volume of 1,059,553. The stock has a market capitalization of $306.06, a price-to-earnings ratio of -7.89 and a beta of 2.44. Marinus Pharmaceuticals has a 52 week low of $1.06 and a 52 week high of $9.87.
Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.02.
In related news, major shareholder Bain Capital Life Sciences Inv sold 822,547 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $8.10, for a total value of $6,662,630.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 6.40% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.